DOP018 Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Abstract

Background: Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life1. We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical practice. Method(s): INSPIRADA was a single-arm, multi-country, open-label study evaluating the effect of ADA on clinical outcomes, costs of care, treatment satisfaction and work productivity in patients with UC treated according to usual clinical practice. Adults with active UC, Physician's Global Assessment (PGA) >=2 and Short Inflammatory Bowel Disease Questionnaire <1% of patients at BL and at Weeks 2, 8 and 26. The overall percentage of patients with any EIM decreased significantly (P